Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer?
Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer?
复制标题
DOI：
10.1053/j.seminoncol.2013.12.014
复制
发表时间：
2014-02
影响因子：
4
通讯作者：
Brahmer JR
中科院分区：
文献类型：
--
作者：
Brahmer JR
在过去的20年里，免疫疗法在临床试验之外的肺癌治疗中没有发挥作用。疫苗的早期试验取得了令人鼓舞的结果，但三期试验尚未显示生存率的改善。最近，免疫检查点途径抑制剂在这类抗体中产生了令人兴奋和一致的活性。然而，三期试验目前正在进行中。目前，给肺癌患者带来免疫治疗的希望就在于这类药物。只有时间才能告诉我们这些抗体是否能提高长期存活率。本综述将重点关注已完成早期试验的检查点通路抑制剂。
Over the past 20 years, immunotherapy has not played a role in the treatment of lung cancer outside of clinical trials. Early trials with vaccines yielded promising results, but phase III trials have yet to show an improvement in survival. Recently, immune checkpoint pathway inhibitors have yielded exciting and consistent activity across this class of antibodies. However, phase III trials are now ongoing. Currently, the hope of bringing immunotherapy to lung cancer patients lies in this class of drugs. Only time will show us if these antibodies will yield an improvement in long-term survival. This review will focus on checkpoint pathway inhibitors that have completed early-phase trials.